Literature DB >> 3994346

Uptake, accumulation, and egress of erythromycin by tissue culture cells of human origin.

J R Martin, P Johnson, M F Miller.   

Abstract

The ability of erythromycin A base to penetrate and accumulate in tissue culture cells of human origin was investigated. The antibiotic was highly concentrated by early passage cells of normal bronchus, kidney, liver, lung, and skin and by cancer cells derived from breast, liver, and lung. Intracellular levels 4 to 12 times that of the extracellular milieu were obtained in both early-passage and transformed cells. The total quantity of erythromycin accumulated depended on the extracellular concentration of antibiotic, but the cellular/extracellular ratios were, for the most part, independent of the initial extracellular drug concentration. In all cell types tested, the accumulated antibiotic rapidly egressed when cells were incubated in antibiotic-free medium. Bioactivity assays demonstrated that the expelled drug was unmetabolized, fully active antibiotic. The concentration of erythromycin by a variety of human cell types probably accounts, in part, for the effectiveness of the antibiotic against intracellular parasites such as Legionella and Chlamydia spp.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994346      PMCID: PMC176268          DOI: 10.1128/AAC.27.3.314

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Distribution and excretion of radioactivity in rats receiving N-methyl-C14-erythromycin.

Authors:  C C LEE; R C ANDERSON; K K CHEN
Journal:  J Pharmacol Exp Ther       Date:  1956-07       Impact factor: 4.030

2.  The effect of antibiotics on the intracellular survival of Staphylococcus aureus in vitro.

Authors:  C S Easmon
Journal:  Br J Exp Pathol       Date:  1979-02

3.  Legionella pneumophila antigen in brain.

Authors:  J M Gatell; J M Miro; M Sasal; O Ferrer; M Rodriguez; J Garcia San Miguel
Journal:  Lancet       Date:  1981-07-25       Impact factor: 79.321

4.  Antibiotic uptake by alveolar macrophages.

Authors:  J D Johnson; W L Hand; J B Francis; N King-Thompson; R W Corwin
Journal:  J Lab Clin Med       Date:  1980-03

5.  Fatal pneumonia caused by Legionella pneumophila, serogroup 3: demonstration of the bacilli in extrathoracic organs.

Authors:  J C Watts; M D Hicklin; B M Thomason; C S Callaway; A J Levine
Journal:  Ann Intern Med       Date:  1980-02       Impact factor: 25.391

6.  Legionnaires' disease bacillus in bone marrow.

Authors:  H M Humayun; T J Bird; J T Daugirdas; R C Fruin; M M Shawky; T S Ing
Journal:  Can Med Assoc J       Date:  1981-11-15       Impact factor: 8.262

7.  Protection of staphylococci ingested by macrophages from the bactericidal action of rifampin.

Authors:  E L Pesanti
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

8.  Legionnaires' disease.

Authors:  D D Weisenburger; H Rappaport; M S Ahluwalia; R Melvani; E D Renner
Journal:  Am J Med       Date:  1980-09       Impact factor: 4.965

9.  Protection of phagocytized bacteria from the killing action of antibiotics.

Authors:  B Holmes; P G Quie; D B Windhorst; B Pollara; R A Good
Journal:  Nature       Date:  1966-06-11       Impact factor: 49.962

10.  Extrapulmonary histopathologic manifestations of Legionnaires' disease: evidence for myocarditis and bacteremia.

Authors:  H J White; W W Felton; C N Sun
Journal:  Arch Pathol Lab Med       Date:  1980-06       Impact factor: 5.534

View more
  22 in total

1.  Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Authors:  S Krasniqi; P Matzneller; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 3.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

4.  Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model.

Authors:  E Azoulay-Dupuis; J Mohler; J P Bédos; C Barau; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 5.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

6.  Immunocytochemistry for amoxicillin and its use for studying uptake of the drug in the intestine, liver, and kidney of rats.

Authors:  Kunio Fujiwara; Masashi Shin; Tsubasa Miyazaki; Yasuhiro Maruta
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

7.  Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.

Authors:  Friederike Traunmüller; Markus Zeitlinger; Petra Zeleny; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

Review 8.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Interactions of dirithromycin with human polymorphonuclear leukocytes.

Authors:  W L Hand; D L Hand
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Measurement of cefaclor and amoxicillin-clavulanic acid levels in middle-ear fluid in patients with acute otitis media.

Authors:  F Scaglione; D Caronzolo; J P Pintucci; F Fraschini
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.